# A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

> **NCT05391061** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 1100 (estimated)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Abrocitinib

## Key facts

- **NCT ID:** NCT05391061
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-07
- **Primary completion:** 2027-11-22
- **Final completion:** 2027-11-22
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05391061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05391061, "A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05391061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*